FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Expect lower flu vax demand in Europe next year

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

After fewer than expected H1N1 influenza cases during last year's flu season in Europe, the industry's top vaccine manufacturers are preparing for lower sales. "In Europe, the pandemic didn't prove to be as threatening as initially thought," Wayne Pisano, head of vaccines at Sanofi-Aventis, told Financial Times. "The response was seen as alarmist." Still, the World Health Organization has listed H1N1 as one of three flu strains that this year's vaccine should inoculate consumers against.

Some countries, including France and Japan, have cancelled large portions of their vaccine orders due to large surpluses this year. The EU only recommends that the elderly and other high-risk groups get vaccinated whereas the U.S.'s advisements apply to everyone. Sanofi-Aventis, GlaxoSmithKline and Novartis all expect upticks in U.S. vaccine demand. The higher U.S. demand will help raise an estimated $6 billion in collective annual sales this year and last. Still, Europeans are more protected against seasonal flu strains than Americans due to the use of adjuvanted vaccines not yet approved in the U.S.

- check out the Financial Times article
- here's the PharmPro story

Related Articles:
H1N1 vax largely unused, almost expired
Experts ponder why regular flu season is a no-show
HHS chief warns of another swine flu outbreak
Britons and Americans turning thumbs down on H1N1 vax


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Novartis   flu vaccine   GlaxoSmithKline   Sanofi-Aventis   H1N1